Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

If you're interested in broad exposure to the Small Cap Value segment of the US equity market, look no further than the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), a passively managed ...

Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a note issued to ...

House Ag Committee Chair Glenn "GT" Thompson speaks to the crowd in a Holstein print bowtie at the ag inaugural ball Jan. 20 The House Agriculture Committee on Thursday released its subcommittee ...

In this piece, we will look at the stocks Jim Cramer recently discussed.